TYLOX Drug Patent Profile
When do Tylox patents expire, and when can generic versions of Tylox launch?
Tylox is a drug marketed by Janssen Pharms and Ortho Mcneil Pharm and is included in three NDAs.
The generic ingredient in TYLOX is acetaminophen; oxycodone hydrochloride; oxycodone terephthalate. There are two drug master file entries for this compound. Additional details are available on the acetaminophen; oxycodone hydrochloride; oxycodone terephthalate profile page.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for TYLOX?
- What are the global sales for TYLOX?
- What is Average Wholesale Price for TYLOX?
Summary for TYLOX
| US Patents: | 0 |
| Applicants: | 2 |
| NDAs: | 3 |
| Raw Ingredient (Bulk) Api Vendors: | 99 |
| DailyMed Link: | TYLOX at DailyMed |
US Patents and Regulatory Information for TYLOX
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Janssen Pharms | TYLOX | acetaminophen; oxycodone hydrochloride | CAPSULE;ORAL | 088790-001 | Dec 12, 1984 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Ortho Mcneil Pharm | TYLOX | acetaminophen; oxycodone hydrochloride; oxycodone terephthalate | CAPSULE;ORAL | 085375-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Ortho Mcneil Pharm | TYLOX-325 | acetaminophen; oxycodone hydrochloride | CAPSULE;ORAL | 088246-001 | Nov 8, 1984 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
TYLOX Market Dynamics and Financial Trajectory
Tylox is a discontinued U.S. brand of oxycodone hydrochloride 5 mg and acetaminophen 500 mg. Its commercial value declined as immediate-release oxycodone/acetaminophen became a generic commodity, opioid prescribing tightened, and manufacturers faced escalating compliance, litigation, and distribution costs. Tylox has no meaningful current branded revenue base, no active biosimilar issue, and limited residual intellectual-property protection. Its remaining market is tied to generic oxycodone/acetaminophen rather than the Tylox trademark.
What is TYLOX and who marketed it?
Tylox was an immediate-release opioid analgesic supplied as a capsule containing:
| Attribute | TYLOX profile |
|---|---|
| Active ingredients | Oxycodone hydrochloride and acetaminophen |
| Strength | 5 mg oxycodone / 500 mg acetaminophen |
| Dosage form | Oral capsule |
| Therapeutic category | Prescription opioid analgesic |
| U.S. regulatory status | Discontinued brand product |
| Generic equivalent | Oxycodone hydrochloride/acetaminophen tablets and capsules |
| Controlled-substance schedule | Schedule II in the United States |
| Current branded revenue | No material publicly reported revenue |
| Biosimilar exposure | None |
Tylox was commercialized in the United States through Johnson & Johnson pharmaceutical operations, including Ortho-McNeil-related entities. The product was one of several branded oxycodone/acetaminophen products competing with Percocet and later generic formulations.
The product’s clinical value came from the combination of oxycodone, a mu-opioid receptor agonist, and acetaminophen. Its commercial differentiation was weak because the same active ingredients were available in numerous generic formulations.
When did TYLOX lose exclusivity?
Tylox lost practical market exclusivity decades ago. The product was approved long before the modern Hatch-Waxman patent and exclusivity framework became commercially important for generic drug launches.
The key exclusivity drivers were:
| Exclusivity element | TYLOX status |
|---|---|
| New chemical entity exclusivity | Not applicable to the mature combination product |
| Orphan-drug exclusivity | None |
| Pediatric exclusivity | None publicly associated with the product |
| Active Orange Book patent protection | No material active patent protection identified |
| Trademark protection | Trademark rights do not prevent generic substitution |
| Generic competition | Established for many years |
| Current brand protection | Commercial rather than patent-based, and effectively absent |
The oxycodone and acetaminophen ingredients are old active pharmaceutical ingredients. Any original composition, formulation, or manufacturing patents associated with Tylox would have expired long before the product’s current commercial period. The Orange Book does not provide a durable patent barrier comparable to those protecting newer branded drugs. The FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations remains the principal source for listed products, patents, exclusivity codes, and therapeutic-equivalence information.[1]
What is the FDA and Orange Book status of TYLOX?
Tylox is not a growth-stage FDA product. Its regulatory position is that of a discontinued brand drug with generic therapeutic substitutes.
The principal regulatory considerations are:
- The product contains a Schedule II opioid.
- Its fixed-dose combination is not protected by modern market exclusivity.
- Generic oxycodone/acetaminophen products compete on price and distribution.
- Discontinuation of a brand product does not eliminate the market for the active ingredients.
- FDA drug-discontinuation records distinguish commercial discontinuation from withdrawal for safety or efficacy reasons.[2]
Tylox should not be confused with a withdrawn product that the FDA determined was unsafe or ineffective. A manufacturer’s discontinuation generally reflects commercial, manufacturing, supply-chain, portfolio, or liability considerations unless FDA records state otherwise.
How large is the current TYLOX market?
The current Tylox-branded market is effectively zero or immaterial. Public company filings do not separately report Tylox revenue, prescription volume, gross margin, or operating profit. Johnson & Johnson reports pharmaceutical performance at broader segment and product-category levels rather than disclosing historical revenue for a mature discontinued opioid brand.[3]
The relevant market is the broader oxycodone/acetaminophen market.
| Market segment | Current commercial condition |
|---|---|
| TYLOX brand | Discontinued and commercially immaterial |
| Generic oxycodone/acetaminophen | Active, price-competitive market |
| Percocet brand | Historically important, but generic substitution dominates |
| Extended-release oxycodone | Separate market with different clinical and regulatory dynamics |
| Immediate-release oxycodone alone | Active generic market |
| Combination opioid analgesics | Contracting or tightly controlled relative to pre-2010 levels |
Because Tylox is no longer a meaningful branded product, market-size estimates based on oxycodone/acetaminophen prescriptions should not be attributed to Tylox. They represent the ingredient market and include products from multiple manufacturers.
What drove the financial decline of TYLOX?
Tylox’s financial trajectory followed the standard pattern for an old combination drug:
Generic substitution
Generic manufacturers competed directly with the active ingredients and dosage strengths. Pharmacy benefit managers and state Medicaid programs favored lower-cost alternatives. Once therapeutic equivalents became available, the brand lost pricing power and formulary access.
Weak product differentiation
Tylox’s capsule presentation did not create a durable clinical advantage over tablets or other immediate-release formulations. The active-ingredient combination was widely available, and prescribers had numerous alternatives.
Opioid prescribing restrictions
Federal and state controls reduced opioid prescribing and increased the administrative burden of dispensing. The Centers for Disease Control and Prevention issued prescribing guidance emphasizing nonopioid treatment where appropriate and limiting opioid exposure for many acute and chronic pain patients.[4]
Acetaminophen safety concerns
The 500 mg acetaminophen component limited the amount of oxycodone that could be taken without increasing acetaminophen exposure. FDA actions involving prescription combination products with more than 325 mg of acetaminophen per dosage unit affected the broader market and encouraged reformulation or discontinuation of higher-acetaminophen products.[5]
Compliance and litigation cost
Opioid manufacturers faced controlled-substance monitoring, suspicious-order reporting, state investigations, federal enforcement actions, and civil litigation. A mature product with little pricing power could not absorb those costs as easily as a protected specialty medicine.
Portfolio rationalization
Manufacturers have generally prioritized higher-value products, generics, specialty drugs, or formulations with stronger commercial positions. A discontinued, commoditized opioid brand is a natural candidate for portfolio exit.
What generic entry risks exist for TYLOX?
Generic entry risk is no longer a future event. It has already occurred and eliminated Tylox’s commercial exclusivity.
The competitive structure includes:
- Generic oxycodone hydrochloride/acetaminophen tablets.
- Generic capsule or equivalent oral formulations where approved.
- Other immediate-release opioid products.
- Nonopioid analgesics.
- State and payer policies favoring generic substitution.
- Institutional purchasing contracts that emphasize price and controlled-substance compliance.
A future generic launch against Tylox would therefore have no meaningful impact on branded revenue. The business risk has shifted from patent-based erosion to market contraction, substitution among generic suppliers, and regulatory restrictions.
Does TYLOX face Paragraph IV challenges?
No economically relevant current Paragraph IV dispute is associated with Tylox.
Paragraph IV certifications matter when an ANDA applicant seeks approval before the expiration of a listed patent. Tylox’s principal patent window expired long ago, and no material active patent estate appears to support a current Paragraph IV strategy. Any historical ANDA challenges would have been relevant only during the period when Orange Book-listed patents remained enforceable.
The absence of a current Paragraph IV dispute reflects the age of the product, not strong patent protection.
What patents protect TYLOX?
No active patent estate is known to provide meaningful commercial protection for Tylox in the United States.
| Patent category | TYLOX position |
|---|---|
| Active-ingredient patents | Expired |
| Combination-product patents | Any original rights expired |
| Formulation patents | No current commercially relevant barrier identified |
| Method-of-use patents | No material active protection identified |
| Manufacturing patents | Cannot block ordinary generic substitution without enforceable, product-relevant claims |
| Device patents | Not applicable to the oral capsule |
| Data exclusivity | Expired |
| Trademark | Does not prevent approval or substitution of generics |
Manufacturing know-how may remain confidential, but it does not create a practical branded moat. For an old oral combination product, generic manufacturers can use independently developed processes and approved formulations.
What formulation patents protect oxycodone/acetaminophen products?
Formulation protection is more relevant to newer opioid products than to Tylox.
Potentially protectable features in the broader category include:
- Abuse-deterrent release mechanisms.
- Extended-release matrices.
- Tamper-resistant dosage forms.
- Modified dissolution profiles.
- Low-dose or reformulated acetaminophen combinations.
- Alternative delivery systems.
Tylox’s immediate-release capsule does not appear to rely on a current abuse-deterrent or extended-release platform. A formulation patent covering a separate oxycodone product would not automatically protect Tylox or prevent generic manufacture of immediate-release oxycodone/acetaminophen.
How strong is the TYLOX patent estate?
The Tylox patent estate is commercially weak.
| Patent-strength factor | Assessment |
|---|---|
| Remaining patent life | None of practical significance |
| Claim differentiation | Limited |
| Formulation complexity | Low |
| Generic manufacturing barriers | Low to moderate |
| Regulatory exclusivity | Expired |
| Trademark value | Minimal after discontinuation |
| Litigation leverage | Minimal |
| Licensing value | Minimal |
The product’s historical value came from regulatory approval, physician familiarity, and distribution, not from a durable patent moat. Those advantages disappeared as generic competitors became available.
Which companies challenge or compete with TYLOX?
Tylox’s relevant competitors are manufacturers of generic oxycodone/acetaminophen and competing opioid analgesics, not companies pursuing the Tylox brand.
The market has included large generic and specialty pharmaceutical manufacturers such as:
- Teva Pharmaceuticals.
- Endo/Par Pharmaceutical.
- Hikma Pharmaceuticals.
- Amneal Pharmaceuticals.
- Mallinckrodt.
- Rhodes Pharmaceuticals.
- Mayne Pharma.
- Other FDA-approved ANDA holders.
The competitive landscape changes as manufacturers enter or exit the market, respond to quota limits, or reduce controlled-substance exposure. Manufacturer-level market share is difficult to attribute from public data because product availability varies by dosage form, wholesaler, payer channel, and supply conditions.
What is the revenue trajectory for TYLOX?
Tylox’s revenue trajectory is best described as:
- Initial branded sales supported by prescription demand and physician recognition.
- Gradual erosion after generic competition.
- Pricing pressure from substitution and payer controls.
- Demand reduction caused by opioid-prescribing restrictions.
- Commercial discontinuation.
- No meaningful current branded revenue.
No public source provides a reliable standalone Tylox revenue series. Company filings aggregate mature products and do not identify Tylox sales separately. Any precise historical revenue estimate would require proprietary prescription, shipment, or sales data.
The product’s economic value today is therefore limited to historical market analysis, trademark records, regulatory history, and potential archival litigation or product-liability review.
What litigation and settlement agreements affect TYLOX?
Tylox was part of the broader prescription-opioid commercial environment, but public opioid litigation generally targeted manufacturers, distributors, and marketing practices at a company or portfolio level rather than assigning a standalone damages stream to Tylox.
Relevant risk categories include:
- State and local opioid lawsuits.
- Distributor suspicious-order investigations.
- Controlled-substance compliance actions.
- Product-liability claims.
- Marketing and promotion allegations.
- Bankruptcy-related opioid settlements.
- State settlement agreements involving major opioid manufacturers and distributors.
The commercial effect was broader than Tylox. Even where a complaint named a manufacturer, the resulting liability exposure was not necessarily allocated by individual brand. Johnson & Johnson and its pharmaceutical subsidiaries entered major opioid-related settlements and resolved substantial litigation at the corporate or portfolio level.[6]
How does TYLOX compare with Percocet?
| Attribute | TYLOX | Percocet |
|---|---|---|
| Active ingredients | Oxycodone/acetaminophen | Oxycodone/acetaminophen |
| Brand status | Discontinued | Brand historically more recognized |
| Generic competition | Extensive | Extensive |
| Patent protection | Expired | Expired or commercially irrelevant |
| Current brand value | Minimal | Limited relative to generics |
| Market distinction | Capsule and brand identity | Stronger historical brand recognition |
| Opioid litigation exposure | Part of broader portfolio risk | Part of broader portfolio risk |
| Current growth outlook | None as a brand | Limited as a brand |
Percocet achieved stronger long-term brand recognition, but the underlying economic structure is similar. Generic oxycodone/acetaminophen products capture most prescription volume and payer value.
What is the outlook for TYLOX and oxycodone/acetaminophen?
Tylox has no credible branded growth pathway in the United States. Reintroduction would face:
- Established generic substitution.
- Limited clinical differentiation.
- Controlled-substance compliance obligations.
- Opioid quota and distribution constraints.
- Reimbursement resistance.
- Product-liability exposure.
- Low willingness among major manufacturers to rebuild an old opioid brand.
The broader oxycodone/acetaminophen market will remain commercially relevant for acute pain, postoperative care, trauma, and selected other indications. Its growth is constrained by opioid stewardship, nonopioid alternatives, state prescribing limits, and payer controls. The market is likely to remain a mature, regulated generic category rather than a branded innovation opportunity.
Key Takeaways
- Tylox is a discontinued U.S. brand of oxycodone hydrochloride 5 mg and acetaminophen 500 mg.
- Its patent and regulatory exclusivity expired long ago.
- Generic oxycodone/acetaminophen competition eliminated meaningful branded pricing power.
- Tylox has no material current branded revenue disclosed by its former commercial sponsors.
- No meaningful current Paragraph IV or biosimilar risk exists.
- Formulation, method-of-use, and manufacturing patents do not create a practical current barrier to generic competition.
- Opioid prescribing restrictions, acetaminophen limits, compliance costs, and litigation reduced the product’s commercial value.
- The relevant market is generic oxycodone/acetaminophen, not Tylox as a standalone brand.
- A Tylox relaunch would have limited commercial logic without a differentiated formulation or delivery system.
FAQs
Is TYLOX still available by prescription?
Tylox is no longer a meaningful actively marketed brand product in the United States. Physicians may prescribe therapeutically equivalent oxycodone/acetaminophen products, generally supplied by generic manufacturers.
Is TYLOX the same as Percocet?
Tylox and Percocet contain the same core active ingredients, oxycodone and acetaminophen, although historical labeling, dosage forms, manufacturers, and inactive ingredients could differ.
Does TYLOX have an active Orange Book patent?
No material active Orange Book patent protection is associated with the mature Tylox product. Its commercial exclusivity ended long ago.
Can a generic manufacturer launch a TYLOX substitute?
Generic manufacturers have already entered the oxycodone/acetaminophen market. A new applicant would compete within the established generic category rather than challenge a commercially protected Tylox brand.
Is TYLOX subject to biosimilar competition?
No. Biosimilars apply to biological products. Tylox is a chemically synthesized small-molecule combination drug and is subject to generic-drug, not biosimilar, competition.
References
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations.
- U.S. Food and Drug Administration. (2024). Drug products and drug product discontinuations.
- Johnson & Johnson. (Various years). Annual report and Form 10-K filings.
- Centers for Disease Control and Prevention. (2022). CDC clinical practice guideline for prescribing opioids for pain.
- U.S. Food and Drug Administration. (2011). Acetaminophen prescription combination products: Drug safety communication.
- U.S. Department of Justice. (2021). Resolution of opioid-related claims involving Johnson & Johnson and Janssen.
More… ↓

